Search alternatives:
significantly improves » significantly improved (Expand Search), significantly improve (Expand Search), significantly improving (Expand Search)
improves decrease » improves disease (Expand Search), improve disease (Expand Search), improved urease (Expand Search)
marked decrease » marked increase (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
Showing 1 - 20 results of 10,548 for search '(( significantly ((we decrease) OR (marked decrease)) ) OR ( significantly improves decrease ))', query time: 0.62s Refine Results
  1. 1
    miRNA 221 improved left ventricular contractile function in MIRI mice.

    miRNA 221 improved left ventricular contractile function in MIRI mice. by Hongyu Li (1332669)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 2
    Significantly Enriched Pathways.

    Significantly Enriched Pathways. by Jiyong Zhang (2498740)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    The linearly decreasing convergence factor a.

    The linearly decreasing convergence factor a. by Junhao Wei (6816803)

    Published 2025
    Save to List
    Saved in:
  4. 4
    Pretreatment of BM-MSCs improves the survival rate and incidence of DCS.

    Pretreatment of BM-MSCs improves the survival rate and incidence of DCS. by Chen Lu (135200)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    Effect of BM-MSCs in improving DCS induced lung injury.

    Effect of BM-MSCs in improving DCS induced lung injury. by Chen Lu (135200)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Mean case duration before and after intervention (t-statistic = -3.35, p <i>< </i>0.001), indicating a statistically significant difference in means.

    Mean case duration before and after intervention (t-statistic = -3.35, p <i>< </i>0.001), indicating a statistically significant difference in means. by Mohammad Bakhtiari (11838264)

    Published 2025
    Save to List
    Saved in:
  7. 7
    Bluetooth beacons with colour coded lanyards.

    Bluetooth beacons with colour coded lanyards. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    EF-24 treatment significantly reduces cell viability in leukemia cell lines.

    EF-24 treatment significantly reduces cell viability in leukemia cell lines. by Ajeet P. Singh (22298432)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
    Save to List
    Saved in:
  10. 10
    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
    Save to List
    Saved in:
  11. 11
    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
    Save to List
    Saved in:
  12. 12
    Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.

    Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index. by Søren Egstrand (10906087)

    Published 2025
    Save to List
    Saved in:
  13. 13
    Table_2_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.xlsx

    Table_2_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.xlsx by Kristin R. Anderson (5478734)

    Published 2024
    Save to List
    Saved in:
  14. 14
    Image_1_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.jpg

    Image_1_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.jpg by Kristin R. Anderson (5478734)

    Published 2024
    Save to List
    Saved in:
  15. 15
    Table_1_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.pdf

    Table_1_A novel anxiety-associated SNP identified in LYNX2 (LYPD1) is associated with decreased protein binding to nicotinic acetylcholine receptors.pdf by Kristin R. Anderson (5478734)

    Published 2024
    Save to List
    Saved in:
  16. 16
    MXene/Bi<sub>2</sub>O<sub>3</sub> Nanocomposites as Supercapacitors for Portable Electronic Devices

    MXene/Bi<sub>2</sub>O<sub>3</sub> Nanocomposites as Supercapacitors for Portable Electronic Devices by Nanasaheb M. Shinde (8560572)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Overview of the WeARTolerance program.

    Overview of the WeARTolerance program. by Ana Beato (20489933)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 18
    The Laboratory Animal Flow Diagram.

    The Laboratory Animal Flow Diagram. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3).

    Pharmacological efficacy of Kylo-0603 in MASH mouse models (F2 ~ 3). by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    General procedure for the synthesis of B.

    General procedure for the synthesis of B. by Xueqin lu (22250795)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: